BEAM Q4 2021 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BEAMBeam Therapeutics Inc.

$3B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51M+851050.0% YoY

Gross Profit

$109M213.9% margin

Operating Income

-$63M-124.3% margin

Net Income

-$65M-126.7% margin

EPS (Diluted)

$-0.95

QoQ Revenue Growth

+6593.2%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

-$12M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$648M

Stockholders' Equity

$827M

Cash & Equivalents

$560M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$6,000	+851050.0%
Gross Profit	$109M	-$32M	+436.7%
Operating Income	-$63M	-$41M	-55.6%
Net Income	-$65M	-$95M	+32.2%